AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15058097 — intervention group
Group type: EXPERIMENTAL
Intervention: Before-Discharge Intervention Method (BDIM)
Number of subjects: 0
Study 15333727 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 d/wk iron supplementation (Ferrous sulfate 300 mg)
Number of subjects: 397
Study 15333727 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 d/wk iron supplementation (Ferrous sulfate 300 mg)
Number of subjects: 397
Study 15333727 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 397
Study 10359248 — intervention group
Group type: EXPERIMENTAL
Intervention: Transected humeral insertion (n = 29)
Number of subjects: 60
Study 10359248 — intervention group
Group type: COMPARATOR
Intervention: Intact humeral insertion (n = 31)
Number of subjects: 60
Study 7866806 — intervention group
Group type: EXPERIMENTAL
Intervention: sulglycotide 200 mg twice daily
Number of subjects: 119
Study 7866806 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 119
Study 1784010 — intervention group
Group type: EXPERIMENTAL
Intervention: Bio-Dis apparatus
Number of subjects: 3
Study 1784010 — intervention group
Group type: COMPARATOR
Intervention: Rotating bottle method
Number of subjects: 3
Study 7058815 — intervention group
Group type: COMPARATOR
Intervention: Keflin®, gentamicin and carbenicillin (KGC)
Number of subjects: 271
Study 7058815 — intervention group
Group type: EXPERIMENTAL
Intervention: KGC
Number of subjects: 271
Study 7058815 — intervention group
Group type: EXPERIMENTAL
Intervention: KGC plus empiric amphotericin B
Number of subjects: 271
Study 7058815 — intervention group
Group type: EXPERIMENTAL
Intervention: KGC plus amphotericin B
Number of subjects: 271
Study 31542382 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured sorting task for classifying dishes based on healthiness and hedonic perception
Number of subjects: 277
Study 31542382 — intervention group
Group type: EXPERIMENTAL
Intervention: Age groups (6-7 years and 8-9 years)
Number of subjects: 277
Study 31542382 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall study findings
Number of subjects: 277
Study 30447565 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline - Clinical Management (CM)
Number of subjects: 162
Study 30447565 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy (IPT)
Number of subjects: 162
Study 30447565 — intervention group
Group type: COMPARATOR
Intervention: Pill Placebo - Clinical Management (CM)
Number of subjects: 162
Study 30447565 — intervention group
Group type: EXPERIMENTAL
Intervention: All conditions (IPT, Sertraline-CM, Pill Placebo-CM)
Number of subjects: 162
Study 29478425 — intervention group
Group type: EXPERIMENTAL
Intervention: Day hospital mentalization-based treatment (MBT-DH)
Number of subjects: 95
Study 29478425 — intervention group
Group type: COMPARATOR
Intervention: Specialist treatment as usual (S-TAU)
Number of subjects: 95
Study 26199066 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic navigation system (RNS) for circumferential pulmonary vein isolation (CPVI)
Number of subjects: 200
Study 26199066 — intervention group
Group type: COMPARATOR
Intervention: Manual ablation
Number of subjects: 200
Study 24612221 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin (50 mg BID)
Number of subjects: 29
Study 24612221 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 22745277 — intervention group
Group type: EXPERIMENTAL
Intervention: Exit site infection (ESI)
Number of subjects: 203
Study 22745277 — intervention group
Group type: COMPARATOR
Intervention: No recent exit site infection (control group)
Number of subjects: 203
Study 20570971 — intervention group
Group type: EXPERIMENTAL
Intervention: Office hysteroscopy
Number of subjects: 678
Study 17903157 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovenous laser (EVL) treatment with a 980‐nm diode, plus clinical treatment
Number of subjects: 52
Study 17903157 — intervention group
Group type: COMPARATOR
Intervention: Clinical treatment (elastic or inelastic compression therapy)
Number of subjects: 52
Study 16086896 — intervention group
Group type: EXPERIMENTAL
Intervention: Atovaquone/proguanil (A/P)
Number of subjects: 24
Study 16086896 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 12297759 — intervention group
Group type: EXPERIMENTAL
Intervention: Argon plasma coagulation
Number of subjects: 30
Study 12297759 — intervention group
Group type: COMPARATOR
Intervention: Observation (Control)
Number of subjects: 30
Study 11692348 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol drops 3 mg/kg plus oral midazolam 0.5 mg/kg
Number of subjects: 50
Study 11692348 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no tramadol)
Number of subjects: 50
Study 11692348 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol drops 3 mg/kg
Number of subjects: 50
Study 7564670 — intervention group
Group type: EXPERIMENTAL
Intervention: Terlipressin combined with glyceryl trinitrate (TER-GTN), intravenous injection (1 to 2 mg)
Number of subjects: 76
Study 7564670 — intervention group
Group type: COMPARATOR
Intervention: Double-placebo injection
Number of subjects: 76
Study 31351062 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvaginal ultrasound + CA125 + human epididymis 4
Number of subjects: 1590
Study 31351062 — intervention group
Group type: COMPARATOR
Intervention: Transvaginal ultrasound + CA125
Number of subjects: 1590
Study 31651877 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dimensional test for treatment effects
Number of subjects: 0
Study 31651877 — intervention group
Group type: COMPARATOR
Intervention: Conventional test for treatment effects
Number of subjects: 0
Study 28399825 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese mothers
Number of subjects: 139
Study 28399825 — intervention group
Group type: COMPARATOR
Intervention: Overweight/normal weight mothers
Number of subjects: 139
Study 28399825 — intervention group
Group type: COMPARATOR
Intervention: Infants
Number of subjects: 139
Study 26163250 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole (1 month preoperative)
Number of subjects: 27
Study 26163250 — intervention group
Group type: COMPARATOR
Intervention: Control (no preoperative itraconazole)
Number of subjects: 27
Study 26030981 — intervention group
Group type: COMPARATOR
Intervention: Pathway 1 FTCs facilitated by case-workers
Number of subjects: 623
Study 26030981 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathway 2 FTCs co-facilitated by caseworkers and a designated/trained facilitator
Number of subjects: 623
Study 26030981 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathway 3 FTCs with family alone time
Number of subjects: 623
Study 26030981 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathway 2 and Pathway 3 FTCs
Number of subjects: 623
Study 21704557 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning blue light (470nm, ∼225lux, n=12)
Number of subjects: 25
Study 21704557 — intervention group
Group type: COMPARATOR
Intervention: Dim light (<1lux, n=13)
Number of subjects: 25
Study 19388972 — intervention group
Group type: EXPERIMENTAL
Intervention: Nateglinide (120 mg three times daily)
Number of subjects: 88
Study 19388972 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 16816796 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 1460
Study 16816796 — intervention group
Group type: COMPARATOR
Intervention: Perphenazine
Number of subjects: 1460
Study 16816796 — intervention group
Group type: COMPARATOR
Intervention: Quetiapine
Number of subjects: 1460
Study 16816796 — intervention group
Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 1460
Study 16816796 — intervention group
Group type: COMPARATOR
Intervention: Ziprasidone
Number of subjects: 1460
Study 15283897 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for prostate, lung, colon, and ovarian cancer
Number of subjects: 155000
Study 15283897 — intervention group
Group type: COMPARATOR
Intervention: Control participants (not specified)
Number of subjects: 155000
Study 11321633 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated and real planes slant judgments
Number of subjects: 0
Study 11321633 — intervention group
Group type: EXPERIMENTAL
Intervention: Texture gradients
Number of subjects: 0
Study 11321633 — intervention group
Group type: EXPERIMENTAL
Intervention: Response method
Number of subjects: 0
Study 9253686 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirometric control during IG test
Number of subjects: 19
Study 9253686 — intervention group
Group type: COMPARATOR
Intervention: Uncontrolled IG test
Number of subjects: 19
Study 9253686 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiration as fast as possible
Number of subjects: 19
Study 9253686 — intervention group
Group type: COMPARATOR
Intervention: Inspiration in 5 seconds
Number of subjects: 19
Study 9253686 — intervention group
Group type: COMPARATOR
Intervention: Inspiration in 10 seconds
Number of subjects: 19
Study 9253686 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuously sucking negative mouth pressure
Number of subjects: 19
Study 9253686 — intervention group
Group type: COMPARATOR
Intervention: Taking one deep breath and holding it for 10 seconds
Number of subjects: 19
Study 8318601 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-in-1 catheter group (n = 20)
Number of subjects: 40
Study 8318601 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 20)
Number of subjects: 40
Study 8318601 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 8318601 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-in-1 catheter group
Number of subjects: 40
Study 3525684 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant systemic antibiotic therapy
Number of subjects: 73
Study 3525684 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 31894620 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthcare utilisation from general hospitals
Number of subjects: 1812
Study 30178600 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin (5 mg/d)
Number of subjects: 57
Study 30178600 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 57
Study 27918670 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined plyometric and strength training (PLY+ST)
Number of subjects: 18
Study 27918670 — intervention group
Group type: COMPARATOR
Intervention: Strength training only (ST)
Number of subjects: 18
Study 26375964 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visit
Number of subjects: 4481
Study 26375964 — intervention group
Group type: COMPARATOR
Intervention: Well-baby clinic visit
Number of subjects: 4481
Study 23939512 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine HCL (single administration paired with the first session of imaginal exposure)
Number of subjects: 40
Study 23939512 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 40
Study 23939512 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine HCL and PE
Number of subjects: 40
Study 22110589 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 ml orange juice daily for 4 weeks
Number of subjects: 10
Study 22110589 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 ml control drink plus hesperidin daily for 4 weeks
Number of subjects: 10
Study 22110589 — intervention group
Group type: COMPARATOR
Intervention: 500 ml control drink and placebo daily for 4 weeks
Number of subjects: 10
Study 19089777 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (600 microg)
Number of subjects: 1620
Study 19089777 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1620
Study 16923110 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib
Number of subjects: 25
Study 16923110 — intervention group
Group type: COMPARATOR
Intervention: Control (other therapies)
Number of subjects: 25
Study 14738099 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine
Number of subjects: 13
Study 14738099 — intervention group
Group type: COMPARATOR
Intervention: Itraconazole
Number of subjects: 13
Study 10912889 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% maltodextrin solution (Md)
Number of subjects: 8
Study 10912889 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Pl)
Number of subjects: 8
Study 9020538 — intervention group
Group type: COMPARATOR
Intervention: Class I alcohol dehydrogenase isoenzymes activity during hospitalization
Number of subjects: 0
Study 9020538 — intervention group
Group type: COMPARATOR
Intervention: Class II alcohol dehydrogenase isoenzymes activity during hospitalization
Number of subjects: 0
Study 9020538 — intervention group
Group type: COMPARATOR
Intervention: Activity of alcohol dehydrogenase isoenzymes over time
Number of subjects: 0
Study 9020538 — intervention group
Group type: COMPARATOR
Intervention: Correlation of alcohol dehydrogenase isoenzymes with other liver enzymes
Number of subjects: 0
Study 18796776 — intervention group
Group type: EXPERIMENTAL
Intervention: Feldenkrais Awareness Through Movement sequence
Number of subjects: 30
Study 3919917 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous hyperalimentation (IVH) for 30 days
Number of subjects: 119
Study 3919917 — intervention group
Group type: COMPARATOR
Intervention: Control group (no IVH)
Number of subjects: 119
Study 29172594 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief motivational interventions (BMIs)
Number of subjects: 252
Study 27010683 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg/day of study medication
Number of subjects: 0
Study 27010683 — intervention group
Group type: COMPARATOR
Intervention: 50 mg/day of study medication (control)
Number of subjects: 0
Study 26311347 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting in the follicular phase
Number of subjects: 7
Study 26311347 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting in the luteal phase
Number of subjects: 7
Study 26311347 — intervention group
Group type: COMPARATOR
Intervention: Meal intake in the follicular phase
Number of subjects: 7
Study 26311347 — intervention group
Group type: COMPARATOR
Intervention: Meal intake in the luteal phase
Number of subjects: 7
Study 24645337 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom monitoring plus feedback (SM + F; n = 49)
Number of subjects: 94
Study 24645337 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC; n = 45)
Number of subjects: 94
Study 21605396 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone/formoterol
Number of subjects: 202
Study 21605396 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone/salmeterol
Number of subjects: 202
Study 18463429 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient supplementation (selenium, vitamin C, and folate) for 8 weeks
Number of subjects: 100
Study 18463429 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 17030973 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally proficient 14-week diet/physical activity intervention (three times weekly)
Number of subjects: 12
Study 17030973 — intervention group
Group type: COMPARATOR
Intervention: General health intervention (control)
Number of subjects: 12
Study 15295782 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft gelatin capsules with vitamin E TPGS (5 mg strength)
Number of subjects: 0
Study 15295782 — intervention group
Group type: COMPARATOR
Intervention: Soft gelatin capsules without vitamin E TPGS (5 mg strength)
Number of subjects: 0
Study 11890241 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (active patient participation in treatment choice)
Number of subjects: 210
Study 11890241 — intervention group
Group type: COMPARATOR
Intervention: Control group (standardized treatment protocols)
Number of subjects: 210
Study 9598228 — intervention group
Group type: EXPERIMENTAL
Intervention: Polytetrafluoroethylene (PTFE) surgical membrane
Number of subjects: 540
Study 9598228 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodegradable polyglycolic acid (PGA) mesh
Number of subjects: 540
Study 7530121 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfuzosin for 24 months (n = 50)
Number of subjects: 518
Study 7530121 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfuzosin for 30 months (n = 22)
Number of subjects: 518
Study 7530121 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfuzosin (long-term treatment)
Number of subjects: 518
Study 7530121 — intervention group
Group type: COMPARATOR
Intervention: Placebo (initial randomization)
Number of subjects: 518
Study 3057844 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone 337.5 mg/day
Number of subjects: 226
Study 3057844 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone 450 mg/day
Number of subjects: 226
Study 3057844 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone 675 mg/day
Number of subjects: 226
Study 3057844 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone 900 mg/day
Number of subjects: 226
Study 3057844 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone (all doses)
Number of subjects: 226
Study 3057844 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 226
Study 30558034 — intervention group
Group type: EXPERIMENTAL
Intervention: Fascia lata allograft
Number of subjects: 44
Study 30558034 — intervention group
Group type: COMPARATOR
Intervention: Gracilis tendon autograft
Number of subjects: 44
Study 27716297 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational intervention
Number of subjects: 394
Study 27716297 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedometer intervention
Number of subjects: 394
Study 27716297 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention
Number of subjects: 394
Study 27716297 — intervention group
Group type: COMPARATOR
Intervention: Control (Health Check only)
Number of subjects: 394
Study 24878943 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradialytic exercise (30 minutes per dialysis session, 3 times a week for 3 months)
Number of subjects: 40
Study 24878943 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 40
Study 22402204 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta
Number of subjects: 181
Study 22402204 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta and low‐dose azathioprine
Number of subjects: 181
Study 22402204 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta, azathioprine and low‐dose prednisone
Number of subjects: 181
Study 19918196 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretching (16 minutes of static stretching using 5 exercises for the major lower body muscle groups)
Number of subjects: 10
Study 19918196 — intervention group
Group type: COMPARATOR
Intervention: Nonstretching (16 minutes of quiet sitting)
Number of subjects: 10
Study 18164827 — intervention group
Group type: COMPARATOR
Intervention: Media resistance skills
Number of subjects: 1318
Study 18164827 — intervention group
Group type: COMPARATOR
Intervention: Drug skill refusal techniques
Number of subjects: 1318
Study 18164827 — intervention group
Group type: COMPARATOR
Intervention: Baseline media resistance skills
Number of subjects: 1318
Study 16357552 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose botulinum toxin (100 units) with short-term electrical stimulation
Number of subjects: 12
Study 16357552 — intervention group
Group type: COMPARATOR
Intervention: High-dose botulinum toxin (400 units)
Number of subjects: 12
Study 12791549 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure Prevention rating method
Number of subjects: 131
Study 12791549 — intervention group
Group type: EXPERIMENTAL
Intervention: Inter-rater reliability assessment by a second hygienist
Number of subjects: 131
Study 11305382 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate fatty cream, applied twice weekly for 6 months
Number of subjects: 68
Study 11305382 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate fatty cream
Number of subjects: 68
Study 8975837 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative low-dose aprotinin (2 million kallikrein inactivator units)
Number of subjects: 57
Study 8975837 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 1535579 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxithromycin 150 mg
Number of subjects: 12
Study 1535579 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxithromycin 300 mg
Number of subjects: 12
Study 1535579 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin 250 mg
Number of subjects: 12
Study 1535579 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin 500 mg
Number of subjects: 12
Study 1535579 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxithromycin vs Clarithromycin
Number of subjects: 12
Study 6142218 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine (100 mg daily)
Number of subjects: 267
Study 6142218 — intervention group
Group type: COMPARATOR
Intervention: No specific treatment (Control)
Number of subjects: 267
Study 31928270 — intervention group
Group type: EXPERIMENTAL
Intervention: New reference values for third-trimester amniotic fluid index (AFI)
Number of subjects: 7037
Study 31928270 — intervention group
Group type: COMPARATOR
Intervention: Comparison with previously published normograms
Number of subjects: 7037
Study 31426450 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple Traffic Lights (MTL)
Number of subjects: 12015
Study 31426450 — intervention group
Group type: COMPARATOR
Intervention: Health Star Rating (HSR)
Number of subjects: 12015
Study 31426450 — intervention group
Group type: COMPARATOR
Intervention: Nutri-Score
Number of subjects: 12015
Study 31426450 — intervention group
Group type: COMPARATOR
Intervention: Reference Intakes (RI)
Number of subjects: 12015
Study 31426450 — intervention group
Group type: COMPARATOR
Intervention: Warning Label
Number of subjects: 12015
Study 30190053 — intervention group
Group type: EXPERIMENTAL
Intervention: Unified Protocol (UP) treatment, 12 weekly sessions
Number of subjects: 64
Study 30190053 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 64
Study 27391572 — intervention group
Group type: EXPERIMENTAL
Intervention: SQ-LNS
Number of subjects: 1320
Study 27391572 — intervention group
Group type: COMPARATOR
Intervention: IFA
Number of subjects: 1320
Study 27391572 — intervention group
Group type: COMPARATOR
Intervention: MMN
Number of subjects: 1320
Study 24603844 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation
Number of subjects: 57
Study 24603844 — intervention group
Group type: EXPERIMENTAL
Intervention: Excluding weekends
Number of subjects: 57